Executive Summary & Key Takeaways
- A New Regulatory Horizon: Artificial intelligence governance, algorithmic accountability, and automated monitoring have emerged as the defining compliance challenges for global life sciences leaders preparing for 2027 enforcement deadlines.
- The Premier European Summit: The 9th Annual Corporate Compliance & Transparency in Life Sciences Conference convenes in Zurich on 17-18 November 2026, gathering over 100 senior directors and 20 thought leaders from Novartis, Roche, Bayer, Amgen, Bristol Myers Squibb, and global oversight bodies.
- Critical Strategic Focus Areas: Key sessions dissect practical compliance for high-risk AI under the EU AI Act, human oversight frameworks, dynamic third-party due diligence, anti-bribery automation, and GDPR erasure rights versus pharmacovigilance mandates.
- High Stakes for Irish Biopharma: With Ireland hosting European headquarters, extensive clinical manufacturing sites, and cross-border commercial hubs, Irish compliance officers must urgently bridge domestic HPRA obligations with sweeping EU-wide digital regulations.
- Exclusive Reader Benefit: Subscribers of Priya Life Science can access an exclusive 20% registration discount on delegate passes using the promotional code corporate20.
The life sciences compliance function is undergoing the most profound structural transformation in its modern history. For decades, healthcare compliance teams focused primarily on traditional touchpoints: static anti-bribery checklists, clear-cut healthcare professional (HCP) interactions, hospitality thresholds, and periodic internal financial audits. However, the convergence of generative artificial intelligence, predictive machine learning in clinical development, complex commercial ecosystems, and increasingly aggressive multi-jurisdictional enforcement has rendered legacy oversight models obsolete.
Today, pharmaceutical, biotechnology, and medical device compliance leaders face an unprecedented regulatory test: AI Governance. Under the European Union Artificial Intelligence Act (EU AI Act), algorithmic tools deployed across diagnostic pipelines, medical affairs content generation, safety signal detection, and digital promotional reviews are subject to rigorous classification, documentation, human oversight, and pre-market conformity assessments. Organizations that fail to institutionalize robust AI governance by 2027 risk catastrophic financial penalties, reputational damage, and commercial disruption.
To address this critical inflection point, the 9th Annual Corporate Compliance & Transparency in Life Sciences Conference will take place on 17-18 November 2026 in Zurich, Switzerland. Organized under the banner theme "Navigating AI, Data, and Global Enforcement in a New Era of Integrity," this two-day executive summit brings together more than 100 senior leaders and over 20 distinguished thought leaders from across Europe and the globe to define the future of healthcare integrity.
The official conference header for the 9th Annual Corporate Compliance & Transparency in Life Sciences summit, held in Zurich on 17-18 November 2026.
Why Irish Life Sciences Leaders Must Anchor in Zurich
For the Irish life sciences sector, the Zurich conference arrives at a pivotal juncture. Ireland is not merely a regional participant in the European healthcare economy; it is Europe's preeminent biopharmaceutical powerhouse. The island serves as the operational home for nine of the world's top ten pharmaceutical corporations, hosting massive manufacturing facilities, global shared service centers, and European commercial headquarters in clusters across Dublin, Cork, Galway, Limerick, Waterford, and Sligo.
Consequently, Irish compliance executives, legal counsels, data protection officers (DPOs), and regulatory directors bear an outsized burden of international compliance complexity. Operating under the dual supervision of the Health Products Regulatory Authority (HPRA) and overarching European Union directives, Irish leadership teams must govern multi-billion-euro international supply chains, clinical development programs, and multi-country commercial distribution networks.
Irish compliance professionals are navigating several urgent pressures:
- EU AI Act Alignment: Ensuring that AI-assisted promotional review tools, predictive pharmacovigilance systems, and diagnostic medical device algorithms deployed across European entities meet the European Commission's stringent high-risk AI criteria.
- Code of Practice Revisions: Managing the practical operational impacts of updated European Federation of Pharmaceutical Industries and Associations (EFPIA) and ABPI Codes of Practice as organizations plan 2027 engagement, financial disclosure, and transfer-of-value transparency strategies.
- Irish Indigenous Representation: The conference features direct contributions from prominent Irish compliance pioneers, including Caroline Kelly, Founder & CEO of Ireland-based Pharma Integrity, who will share practical strategies for implementing ethical culture and regulatory compliance frameworks.
- Cross-Border Distributor Oversight: Transitioning from passive annual due diligence questionnaires to real-time, automated risk sensing networks that monitor third-party intermediaries and clinical contract partners across EMEA.
The four strategic objectives of the Zurich summit: Finalizing 2027 regulatory readiness, monitoring European enforcement, tackling next-generation AI challenges, and connecting Europe's compliance leadership.
As noted by Marina Relly of PNewport Pharmaceuticals in Ireland following a previous edition: "Great networking. Very informative, with a lot of practical examples from industry and patients." The 2026 programme in Zurich is specifically designed to provide Irish teams with battle-tested peer methodologies that turn complex compliance mandates into defensible commercial advantages.
From Gatekeeper to Strategic Futurist: The 2030 Compliance Function
The conference opens on 17 November with a visionary keynote address by Brett Hudson, Vice President of Ethics, Risk & Compliance at Novartis, titled "The 2030 Compliance Officer: From Gatekeeper to Strategic Futurist." Hudson will examine how artificial intelligence, predictive risk scoring, and workflow automation are radically reshaping the corporate compliance function.
By 2030, compliance leaders will no longer serve merely as administrative gatekeepers or post-incident investigators. Instead, the function requires a fundamental re-skilling around data science literacy, strategic regulatory foresight, and ethical systems architecture. Compliance teams must embed proactive guardrails into product innovation cycles from day one, anticipating the complex regulatory intersections between personalized gene therapies, connected digital medical devices, and automated clinical software.
Following the keynote, Bella Hovhannisyan, Chief Ethics & Compliance Officer at CSL, will lead a strategic spotlight on indirect influence and ecosystem risks in third-party engagement. Her session tackles where global regulatory bodies are drawing the line regarding healthcare professional (HCP) founded entities, charitable foundations, and medical associations, offering an actionable governance checklist for executive boards.
Opening keynote speaker Brett Hudson (Novartis) alongside distinguished compliance leaders from CSL, Novo Nordisk, WHO Foundation, Bristol Myers Squibb, Bayer, Roche, Amgen, and Baxter.
High-Risk AI Systems, MDR/IVDR Intersection, and Human Oversight
Artificial intelligence governance remains the central analytical pillar throughout the Zurich agenda. A premier morning panel featuring Bella Hovhannisyan (CSL), Caroline Onyango-Dyregaard (Associate Director, Head of Governance, Risk, Ethics & Compliance at the WHO Foundation), Brett Hudson (Novartis), and Chris Muehl (Senior Executive in Ethics, Risk & Compliance, formerly with GSK, Alnylam, Novartis, and BMS) will decode the exact obligations facing life sciences organizations under the EU AI Act.
Crucially, the panel will assess early enforcement actions by National Competent Authorities across European member states and address the complex regulatory friction between the EU AI Act and existing Medical Device Regulation (MDR) and In Vitro Diagnostic Regulation (IVDR) obligations. Key areas of operational focus include:
- Mandatory AI Literacy: Establishing cross-functional training frameworks across clinical research, regulatory affairs, commercial marketing, and legal departments to satisfy statutory literacy benchmarks.
- Meaningful Human-in-the-Loop Oversight: In a dedicated presentation, Alex Davison, Compliance Director for Europe and Global Projects at Amarin Corporation, will review human oversight standards under the AI Act, sharing real-world case studies of AI in promotional materials review, safety signal detection, and patient support chatbots.
- Proving Supervisory Rigor: Developing auditable technical documentation, algorithmic validation logs, and prompt-tracking workflows that withstand rigorous regulatory inspections.
Dynamic Third-Party Risk, Anti-Corruption, and Multi-Jurisdictional Scrutiny
As biopharmaceutical supply chains fragment globally, managing third-party risks has become significantly more perilous. On the afternoon of Day 1, Anastasiya Troyan, Senior Director of External Engagements at Novartis, explores hidden indirect influence risks within foundations, patient organizations, and HCP-founded ventures, illuminating critical due diligence blind spots exposed in recent cross-border enforcement penalties.
On Day 2, the enforcement landscape takes center stage. Kersten Schmahl, Head of Ethics & Compliance International at CSL, will lead a high-level panel examining global anti-corruption enforcement priorities across the U.S. Department of Justice (DOJ), Securities and Exchange Commission (SEC), and European national prosecutors. The panel brings together distinguished authorities including Francesco Clementucci, Senior Integrity Risk Specialist for Europe and Central Asia at The World Bank Group, alongside senior compliance leaders from Amgen and Bristol Myers Squibb.
Esteemed governance faculty featuring Irish compliance executive Caroline Kelly (Founder & CEO, Pharma Integrity) alongside experts from Alnylam, Amarin, Chiesi, Arcera Lifesciences, and GCO Global.
Speakers will examine how international enforcement agencies are increasingly deploying advanced data analytics, natural language processing, and forensic accounting algorithms to uncover overseas bribery and corrupt referral schemes. Organizations can no longer rely on paper policies; compliance programs must prove real-time detection, automated auditing, and demonstrable operational effectiveness.
Data Privacy Tightropes: Genomic Architecture vs. GDPR Erasure Rights
The advent of personalized medicine, cell and gene therapies, and digital companion diagnostics has created acute tensions between patient privacy rights and mandatory pharmacovigilance duties. In a highly anticipated session, Luca Fiormonti, Senior Privacy Counsel at Chiesi Farmaceutici, addresses "The Right to be Forgotten vs. Pharmacovigilance: A Compliance Tightrope."
Fiormonti will analyze the legal mechanics of reconciling GDPR Article 17 erasure requests with mandatory multi-decade adverse event tracking requirements under European Medicines Agency (EMA) and HPRA mandates. Delegates will receive practical guidance on architecting compliant data pseudonymization, cryptographic anonymization pipelines, and defensible scientific retention schedules that satisfy both data protection commissioners and drug safety inspectors.
2026-2027 Life Sciences Compliance Matrix
To help compliance executives, legal directors, and regulatory managers evaluate the key programme components and their direct organizational impact, the following matrix summarizes the conference pillars, distinguished speakers, regulatory drivers, and practical implications for Irish and European operations:
The Team Behind the Event & Zurich as Europe's Premier Compliance Capital
The Corporate Compliance & Transparency in Life Sciences summit is produced by Fleming, Europe's foremost organizer of high-impact life sciences conferences. Backed by an experienced industry production team including Mate Buki (Life Sciences Manager), David Horti (Business Development Manager), Viktoria Dzurjuvova (Marketing Manager), and Neelima Chand (Sales Director), the summit ensures rigorous curation, practical case studies, and senior-level attendee qualification.
Hosted in Zurich, Switzerland, the setting provides an exceptional venue for strategic dialogue. Frequently ranked as the world's top city for quality of life, Zurich combines world-class infrastructure and financial stability with a thriving pharmaceutical and biotechnology presence, making it the ideal neutral ground for European compliance leaders to network, benchmark, and collaborate.
The executive production team behind the summit, set against the historic skyline and riverfront of Zurich, Switzerland.
Secure Your Delegate Registration: Exclusive 20% Discount for Priya Life Science Readers
The Corporate Compliance & Transparency in Life Sciences Conference in Zurich represents an essential strategic investment for leadership teams seeking to future-proof their regulatory posture before the close of 2026. With over six hours of structured executive networking, interactive roundtables, real-time polling, and intimate case study dissections, attendance is strictly capped to ensure peer-level collaboration.
As an official media partner, Priya Life Science has secured an exclusive 20% discount on all delegate registration packages for our readers, corporate subscribers, and life sciences network. To claim your 20% reduction, apply the promotional code corporate20 during online checkout or quote the code directly when contacting the organizers.
Corporate Compliance & Transparency in Life Sciences 2026
Dates: 17-18 November 2026 | Venue: Zurich, Switzerland
Join senior ethics, compliance, privacy, and regulatory directors from Novartis, Roche, Bayer, Amgen, and BMS to master AI governance and 2027 compliance mandates.
Frequently Asked Questions (FAQ)
Q1: When and where will the conference take place?
The 9th Annual Corporate Compliance & Transparency in Life Sciences Conference will be held on 17-18 November 2026 in Zurich, Switzerland. Full venue and travel information is provided to registered delegates by Fleming.
Q2: What are the primary regulatory themes addressed in the 2026 agenda?
The programme centers on the EU AI Act and algorithmic governance, human-in-the-loop validation, dynamic third-party risk management, multi-jurisdictional anti-corruption enforcement, GDPR right to be forgotten versus pharmacovigilance retention, and ethical patient engagement models.
Q3: Which major life sciences organizations and institutions are contributing?
Speakers include senior vice presidents, legal counsels, and ethics heads from Novartis, CSL, Novo Nordisk, WHO Foundation, Bristol Myers Squibb, Bayer, Roche, Amgen, Baxter, Chiesi Farmaceutici, Alnylam Pharmaceuticals, Pharma Integrity Ireland, Transparency International, and The World Bank Group.
Q4: How do I claim the 20% discount on conference registration?
Subscribers of Priya Life Science can apply the promotional code corporate20 when registering through the official Fleming event portal or scan the QR code featured above to activate the discount automatically.
Q5: Why is this European conference specifically vital for Irish life sciences companies?
Ireland hosts extensive commercial hubs, global manufacturing sites, and EMEA headquarters for the world's leading biopharma innovators. As national competent authorities begin enforcing EU AI Act mandates alongside HPRA standards, Irish compliance leaders need direct insights from EU regulators and peers to ensure complete 2027 compliance readiness.
